Skip to main content
Tessa NewsLink
Paste a health news link, or browse
Latest checks

Source study found

Story checked

A big win for Foundayo: GLP-1 pill orforglipron helps patients lose weight, protect their hearts (opens in a new tab)

cardiovascularbusiness.com · 2026-10-05

Short answerEvidenceSource

Short answer

Mixed

Mixed.

One claim goes further than the study. 3 other points were not covered by the paper.

  • 2 supported
  • 1 overstated
  • 3 not covered

Checked against the study summary. The full text wasn't available, so some details couldn't be settled either way.

Share this check

Follow the evidence trail
1

The story

A big win for Foundayo: GLP-1 pill orforglipron helps patients lose weight, protect their hearts

cardiovascularbusiness.com · 2026-10-05

The story’s checkable claims.

Read the original story (opens in a new tab)
2

NewsLink checks it

Mixed

One claim overstates the study. Two of six check out. Three claims the study doesn't address.

  • 2 supported
  • 1 overstated
  • 3 not covered
Open claim evidence
3
Then inspect each claim

Evidence layer

Claim by claim

Each claim gets a verdict. Expand it to see the evidence directly below.

6 claims in this story

Showing all 6 claimsChoose a verdict to focus the list.

Claim 1 of 6OverstatedOrforglipron, a GLP-1 pill sold by Eli Lilly under the brand name Foundayo, is both safe and effective in obese or overweight patients with type 2 diabetes.View evidenceHide evidence

Why this verdict

The abstract profile supports a narrower conclusion: in ACHIEVE-4, orforglipron met prespecified cardiovascular non-inferiority versus insulin glargine for MACE-4 in adults with type 2 diabetes, BMI ≥25 kg/m2, and increased cardiovascular risk. It also reports safety/tolerability outcomes, including substantially more gastrointestinal adverse events with orforglipron. The story’s unhedged lead framing that the drug is broadly “safe and effective” in obese or overweight patients with type 2 diabetes outruns the abstract-level evidence, which is primarily cardiovascular safety/non-inferiority and selected safety reporting, not broad efficacy.

1

Study evidence

Orforglipron met the prespecified non-inferiority criterion versus insulin glargine for time-to-first MACE-4 over a median follow-up of 2 years.HR 0.84 (95% CI 0.59–1.20); p<0.0001 for non-inferiority (upper 95% CI <1.8).

“This event-driven, phase 3, multicentre, randomised, open-label, active comparator, parallel-group study was conducted in 317 sites across 16 countries and territories.”
2

Study evidence

Gastrointestinal adverse events were reported in 851 of 1371 participants (62.1%) receiving orforglipron versus 193 of 1355 participants (14.2%) receiving insulin glargine.62.1% vs 14.2% (851/1371 vs 193/1355)

“The primary endpoint and other safety endpoints were assessed in all participants who took at least one dose of assigned treatment”
Claim 2 of 6Not coveredThe primary takeaway from the new data was presented at the European Association for the Study of Diabetes annual meeting and simultaneously published in The Lancet.View evidenceHide evidence

Why this verdict

The supplied abstract-level paper profile does not contain evidence about presentation at the European Association for the Study of Diabetes annual meeting or simultaneous publication logistics in The Lancet. This provenance/timing claim cannot be verified from the provided profile.

Claim 3 of 6Not coveredOrforglipron was also associated with a 23% lower risk of a composite outcome limited to cardiovascular death, heart attack, and stroke.View evidenceHide evidence

As stated23% lower risk

Why this verdict

The provided abstract profile reports the four-component MACE-4 primary endpoint, but it does not provide a separate result for a three-component composite limited to cardiovascular death, myocardial infarction, and stroke. The claimed 23% lower risk for that different composite cannot be verified at the supplied abstract depth.

1

Study evidence

Orforglipron met the prespecified non-inferiority criterion versus insulin glargine for time-to-first MACE-4 over a median follow-up of 2 years.HR 0.84 (95% CI 0.59–1.20); p<0.0001 for non-inferiority (upper 95% CI <1.8).

“This event-driven, phase 3, multicentre, randomised, open-label, active comparator, parallel-group study was conducted in 317 sites across 16 countries and territories.”
Claim 4 of 6Not coveredPatients given orforglipron consistently reported substantial weight loss and reductions in waist circumference, systolic blood pressure, triglycerides, non-HDL cholesterol, and high-sensitivity C-reactive protein.View evidenceHide evidence

Why this verdict

The supplied abstract profile does not report weight loss, waist circumference, systolic blood pressure, triglycerides, non-HDL cholesterol, or high-sensitivity C-reactive protein outcomes. These claimed cardiometabolic marker improvements may come from fuller data, but they are not verifiable from the provided abstract-level profile.

1

Study evidence

Orforglipron met the prespecified non-inferiority criterion versus insulin glargine for time-to-first MACE-4 over a median follow-up of 2 years.HR 0.84 (95% CI 0.59–1.20); p<0.0001 for non-inferiority (upper 95% CI <1.8).

“This event-driven, phase 3, multicentre, randomised, open-label, active comparator, parallel-group study was conducted in 317 sites across 16 countries and territories.”
Claim 5 of 6SupportedACHIEVE-4 was a randomized trial of more than 2,700 patients who received either orforglipron or insulin glargine.View evidenceHide evidence

As statedmore than 2,700 patients

Why this verdict

The profile states that ACHIEVE-4 was a phase 3, multicentre, randomised, open-label, active-comparator trial with 2749 participants randomised 1:1 to oral orforglipron or injectable titrated insulin glargine, which supports the story’s “more than 2,700 patients” randomized-trial description.

1

Study evidence

Orforglipron met the prespecified non-inferiority criterion versus insulin glargine for time-to-first MACE-4 over a median follow-up of 2 years.HR 0.84 (95% CI 0.59–1.20); p<0.0001 for non-inferiority (upper 95% CI <1.8).

“This event-driven, phase 3, multicentre, randomised, open-label, active comparator, parallel-group study was conducted in 317 sites across 16 countries and territories.”
Claim 6 of 6SupportedOrforglipron was associated with a 16% lower risk of major adverse cardiovascular events than insulin glargine, meeting prespecified noninferiority criteria.View evidenceHide evidence

As stated16% lower risk

Why this verdict

The abstract profile reports the primary MACE-4 result as HR 0.84 for orforglipron versus insulin glargine, equivalent to a 16% lower hazard estimate, with 95% CI 0.59–1.20 and p<0.0001 for non-inferiority under the prespecified margin. The story frames this as an association and notes non-inferiority, so it does not claim proven superiority.

1

Study evidence

Orforglipron met the prespecified non-inferiority criterion versus insulin glargine for time-to-first MACE-4 over a median follow-up of 2 years.HR 0.84 (95% CI 0.59–1.20); p<0.0001 for non-inferiority (upper 95% CI <1.8).

“This event-driven, phase 3, multicentre, randomised, open-label, active comparator, parallel-group study was conducted in 317 sites across 16 countries and territories.”
Then look for missing context

Context layer

What the story left out

Important study details the story did not include.

  • The enrolled population was adults with type 2 diabetes, BMI ≥25 kg/m2, HbA1c 7.0–10.5%, and increased cardiovascular risk; 85.9% had established cardiovascular disease.

    The story captures overweight/obesity and type 2 diabetes but omits the increased-cardiovascular-risk eligibility and high prevalence of established cardiovascular disease, which limits generalization to all overweight or obese patients with type 2 diabetes.

    From Event-driven, multicentre, randomised, open-label, active comparator, parallel-group, phase 3 trial

  • Gastrointestinal adverse events were much more frequent with orforglipron than insulin glargine: 62.1% versus 14.2%, and GI events were the most common reason for orforglipron discontinuation.

    This is a central safety/tolerability finding in the abstract. The story’s broad “safe” framing is not balanced, in the supplied presentation, by this important adverse-event burden.

    From Phase 3, multicentre, randomised, open-label, active-comparator trial (safety population analysis)

  • Clinically significant or severe hypoglycaemia occurred less often with orforglipron than insulin glargine: 6.8% versus 19.2%.

    This favorable safety comparison is reported in the abstract but is not specifically reflected in the supplied story claims or caveats.

    From Phase 3, multicentre, randomised, open-label, active-comparator trial (safety population analysis)

  • Deaths were numerically lower with orforglipron than insulin glargine, 1.4% versus 3.2%, but the abstract provides limited cause-specific and adjudication detail.

    The story presentation does not reflect the mortality counts or the abstract-level limitation that detailed cause-specific/adjudication information is not provided.

    From Phase 3, multicentre, randomised, open-label, active-comparator trial (safety population analysis)

3 things the story did carry across
  • ACHIEVE-4 was an event-driven, phase 3, multicentre, randomised, open-label, active-comparator, parallel-group trial comparing oral orforglipron with injectable titrated insulin glargine.
  • The primary endpoint was time-to-first four-component MACE: cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, or hospitalization for unstable angina.
  • The primary cardiovascular result was non-inferiority, not demonstrated superiority: HR 0.84, 95% CI 0.59–1.20, with the upper confidence bound below the prespecified non-inferiority margin of 1.8.
Then read the study layer

Study layer

Study at a glance

Scan the study first. Expand only the parts you want to inspect.

Pieces of work

2

Evidence read

study summary

Lead result

human in vivo

1Lead resulthuman in vivoAssess cardiovascular safety of orforglipron vs insulin glargine by testing non-inferiority on time-to-first MACE-4 in adults with type 2 diabetes at increased cardiovascular risk (ACHIEVE-4).Event-driven, multicentre, randomised, open-label, active comparator, parallel-group, phase 3 trialExpand

In plain English

Phase 3, event-driven, multicentre, randomised, open-label trial (ACHIEVE-4) comparing oral orforglipron versus injectable insulin glargine in adults with type 2 diabetes at increased cardiovascular risk, with prespecified primary non-inferiority analysis of time-to-first four-component MACE (MACE-4). Over a median 2-year follow-up, orforglipron demonstrated non-inferiority to insulin glargine for MACE-4 (HR 0.84, 95% CI 0.59–1.20; p<0.0001 for non-inferiority using an upper 95% CI margin <1.8).

Key findings

  • Orforglipron met the prespecified non-inferiority criterion versus insulin glargine for time-to-first MACE-4 over a median follow-up of 2 years.HR 0.84 (95% CI 0.59–1.20); p<0.0001 for non-inferiority (upper 95% CI <1.8).
  • Gastrointestinal adverse events were substantially more frequent with orforglipron than with insulin glargine.62.1% (851/1371) with orforglipron vs 14.2% (193/1355) with insulin glargine.
“This event-driven, phase 3, multicentre, randomised, open-label, active comparator, parallel-group study was conducted in 317 sites across 16 countries and territories.”
What this piece can’t prove
  • Open-label trial design (stated in abstract).
  • Study funded by Eli Lilly and Company (disclosed in abstract).

1 further detail could not be confirmed from the summary.

2human in vivoCompare overall safety and tolerability between orforglipron and insulin glargine (adverse events, hypoglycaemia, deaths/discontinuations) in the randomized trial.Phase 3, multicentre, randomised, open-label, active-comparator trial (safety population analysis)Expand

In plain English

In this phase 3 randomized, open-label trial safety population (all participants receiving ≥1 dose, followed from baseline until withdrawal/completion), gastrointestinal adverse events were substantially more frequent with oral orforglipron than with injectable insulin glargine, clinically significant/severe hypoglycaemia (glucose <3 mmol/L [54 mg/dL]) was less frequent with orforglipron, and total deaths were numerically lower in the orforglipron arm; the abstract reports these safety/tolerability outcomes without providing detailed AE severity or adjudication tables.

Key findings

  • Gastrointestinal adverse events were reported in 851 of 1371 participants (62.1%) receiving orforglipron versus 193 of 1355 participants (14.2%) receiving insulin glargine.62.1% vs 14.2% (851/1371 vs 193/1355)
  • Clinically significant or severe hypoglycaemia (glucose <3 mmol/L [54 mg/dL]) occurred in 93 of 1371 participants (6.8%) receiving orforglipron versus 260 of 1355 participants (19.2%) receiving insulin glargine.6.8% vs 19.2% (93/1371 vs 260/1355)
“The primary endpoint and other safety endpoints were assessed in all participants who took at least one dose of assigned treatment”
What this piece can’t prove
  • Reporting is limited to the abstract: detailed AE tables, timing, severity grades, seriousness, and cause-specific adjudication are not provided.
  • Open-label design may introduce reporting bias for subjective adverse events (e.g., gastrointestinal symptoms).
  • The abstract does not specify methods for AE ascertainment (active surveillance vs passive reporting), nor does it report statistical tests or confidence intervals for the presented safety comparisons.

1 further detail could not be confirmed from the summary.

Finally, the search trail

Method layer

NewsLink found the paper. Tessa takes you deeper.

NewsLink checks the story. Tessa is where you inspect the paper, authors, evidence, and research context.

Open the paper in Tessa

Cardiovascular safety of orforglipron versus insulin glargine in adults with type 2 diabetes at increased cardiovascular risk (ACHIEVE-4): a phase 3, event-driven, randomised, open-label, non-inferiority, active comparator trial

Lancet (London, England) · 2026

Deep dive in Tessa (opens in a new tab)Source record (opens in a new tab)

Why this one

Near certain

NewsLink found the paper. Tessa is where you inspect it deeply.

Papers considered

The selected paper, plus nearby candidates.

PubMed, Europe PMC, Crossref · 40 candidate papers

Selected

Cardiovascular safety of orforglipron versus insulin glargine in adults with type 2 diabetes at increased cardiovascular risk (ACHIEVE-4): a phase 3, event-driven, randomised, open-label, non-inferiority, active comparator trial

Lancet (London, England) · 2026 · PubMed, Europe PMC, Crossref

Tessa (opens in a new tab)Source (opens in a new tab)
Candidate

A multifaceted intervention to improve syphilis screening and treatment in pregnant women in Kinshasa, Democratic Republic of the Congo and in Lusaka, Zambia: a cluster randomised controlled trial.

The Lancet. Global Health · 2019 · PubMed

Tessa (opens in a new tab)Source (opens in a new tab)

And 34 more candidates considered.